מחיר לרווח עתידי Regulus (RGLS)
The expected price-to-earnings multiple of Regulus Therapeutics (RGLS) correlates with its scientific alliances with pharma behemoths to combat renal pathologies. Diversified oligonucleotide supplies ensure the continuity of research. Future revenues are based on the commercialization of microRNA therapy for rare genetic diseases. The value of 0.00 serves as the current parameter value, capturing the current asset valuation phase on this chart.
פילוחי מדדים פיננסיים ומדדי שוק עבור Regulus (RGLS)
Portfolio managers are evaluating the operating model of Regulus Therapeutics (RGLS) through the company's forward P/E ratio, which compares current market capitalization with expected net income to determine the asset's degree of overbought status. The value of 0.00 on the chart reflects market expectations amid a lack of revenue and a dependence on R&D, where any gap between the price and actual successes in RNA therapy signals high volatility.
